SuperworthAdma Biologics market cap ADMA
Share price times shares outstanding: what the whole company sells for, since 2013.
- Today, Oct 23, 2026
- $2.4B
- Highest close in our data
- $5.6B
- May 2025
Adma Biologics is worth $2.4B at the close on Oct 23, 2026, at $10.68 a share.
That is down 34% over the last year and up 1297% over five years.
Its highest close in our data was $5.6B in May 2025.
Market cap over time
Year by year
| Year | End of year | Low | High | Change |
|---|---|---|---|---|
| 2026 so far | $2.4B | $1.8B | $4.3B | −48% |
| 2025 | $4.6B | $3.4B | $5.6B | +11% |
| 2024 | $4.1B | $994.3M | $5.3B | +304% |
| 2023 | $1B | $608M | $1B | +34% |
| 2022 | $763.5M | $260.4M | $763.5M | +177% |
| 2021 | $276.1M | $146M | $325.1M | +50% |
| 2020 | $184.4M | $171.8M | $308.3M | −21% |
| 2019 | $234.3M | $128.4M | $315.6M | +127% |
| 2018 | $103.4M | $83.3M | $296.2M | +25% |
| 2017 | $82.8M | $37.9M | $89.2M | +25% |
| 2016 | $66M | $44.5M | $101.2M | −24% |
| 2015 | $86.5M | $72M | $106.4M | −16% |
| 2014 | $103.1M | $68.3M | $115.7M | +63% |
| 2013 | $63.2M | $47.8M | $78.4M | n/a |
Against its peers
Companies in Biotechnology nearest Adma Biologics' size, closest first, today.
| Company | Market cap |
|---|---|
| ADMAAdma Biologics | $2.4B |
| VCELVericel | $2.2B |
| MGTXMeiraGTx | $884.6M |
| KRYSKrystal Biotech | $9.2B |
| RGENRepligen | $10B |
| TECHBIO-TECHNE | $11.4B |
| HALOHalozyme Therapeutics | $14.3B |
| NBIXNeurocrine Biosciences | $14.5B |
| EXELExelixis | $16B |
| INCYIncyte | $23.5B |
| Peer median | $11.4B |
What the market cap tells you
Share price times shares outstanding: what the whole company sells for today.
Size, not quality. Large caps move slower and are covered more. That is all it tells you.
More on Adma Biologics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.